Cold Therapy Offers Promising Prevention Against Taxane-Induced Dermatologic Events

After systematically reviewing 34 studies, researchers have found skin cooling methods may be the best preventative intervention against taxane-based chemotherapy side effects

WASHINGTON (Oct. 31, 2018) - Due to their broad antitumor activity that inhibits the function of microtubules, taxanes are common chemotherapeutic agents utilized for the management of multiple cancer types from breast to prostate. Unfortunately, the frequency of their use is equally matched by the rates of expected and well known side effects.

In fact, chemotherapy-induced alopecia as well as nail and skin changes occur in up to 89 percent of patients receiving taxane-based chemotherapy. While common, preventative strategies and therapeutic interventions are not well established, including cold therapy, over the counter and prescription topical treatments, and even systemic corticosteroids.

Researchers at the George Washington University (GW) have found that cooling therapies such as cold caps, scalp cooling systems, frozen gloves, and frozen socks may offer the best protection against the adverse effects of taxane-based chemotherapy.

“Taxanes induce dermatologic changes through direct cytotoxic effect," said Adam Friedman, MD, director of the Supportive Oncodermatology Clinic at the GW Cancer Center, professor of dermatology at the GW School of Medicine and Health Sciences, and senior author on the study. “While they are an important tool in our chemotherapy armamentarium, cutaneous side effects can limit their use and therefore we want to establish the best approaches, both prophylactic and active, to limit their negative impact."

Friedman and his team at GW performed a comprehensive systematic review of 34 studies published between Jan. 1, 1980 and Aug. 13, 2018 to assess the efficacy and safety of interventions to prevent taxane-induced dermatologic adverse effects.

The team found cold therapy offers the most promising preventative intervention for taxane-induced dermatologic events, followed by urea-based creams specifically for hand/foot side effects, while off-label use of topical lovastatin and systemic corticosteroids did not provide adequate protection.

“Most of the studies we looked at support the use of cold caps or scalp cooling systems to reduce hair loss," Friedman explained. “These seem to be the most effective in preventing taxane-induced alopecia, and there is even evidence supporting their ability to prevent toxic events affecting both the skin of the hands/feet and the nails."

Additional research is need to establish routine protocols for cooling methods and to identify new approaches to mitigate these adverse events, said Friedman. Researchers must also determine more standardized outcome measures for successful hair, skin, and nail injury prevention, and the long-term efficacy and safety of these interventions.

The study, titled “Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events," is published in JAMA Dermatology and available at https://jamanetwork.com/journals/jamadermatology/fullarticle/2711245.

Media: To interview Dr. Friedman, please contact Ashley Rizzardo at amrizz713@gwu.edu or 202-994-8679.

###

About the GW Cancer Center

The George Washington University (GW) Cancer Center is a collaboration of the George Washington University, the GW Hospital and the GW Medical Faculty Associates to expand GW’s efforts in the fight against cancer. The GW Cancer Center also incorporates all existing cancer-related activities at GW, with a vision to create a cancer-free world through groundbreaking research, innovative education and equitable care for all. Learn more about the GW Cancer Center at gwcancercenter.org.

Latest News

The George Washington University (GW) Cancer Center has achieved internationally recognized accreditation for cellular therapy and stem cell transplantation from the Foundation for the Accreditation of Cellular Therapy (FACT).
The George Washington (GW) Cancer Center is pleased to announce the addition of Melissa Bucklin, PA-C, to its team as a Gynecologic Oncology Physician Assistant (PA).
Doug Evans looks at the world through different lenses. As the Director of the BRIGHT Institute at the Milken Institute School of Public Health, he leads research on the influence of digital technology on public health behaviors. As a collector of old and inaccurate maps, he sees the world through…